Literature DB >> 11416032

Activation of the insulin-like growth factor 1 signaling pathway by the antiapoptotic agents aurintricarboxylic acid and evans blue.

R Beery1, M Haimsohn, N Wertheim, R Hemi, U Nir, A Karasik, H Kanety, A Geier.   

Abstract

Aurintricarboxylic acid (ATA), an endonuclease inhibitor, prevents the death of a variety of cell types in culture. Previously we have shown that ATA, similar to insulin-like growth factor I (IGF-I), protected MCF-7 cells against apoptotic death induced by the protein synthesis inhibitor cycloheximide. Here we show that ATA and a polysulfonated aromatic compound, Evans blue (EB), similar to IGF-I, promote survival and increase proliferation of MCF-7 cells in serum-free culture medium. This may suggest a common signaling pathway shared by the aromatic polyanions and IGF-I. Therefore, the ability of these aromatic compounds to activate the signal transduction pathway of IGF-I was examined. We found that ATA and EB mimicked the IGF-I effect on tyrosine phosphorylation of the IGF-I receptor (IGF-IR) and its major substrates, insulin receptor substrate-1 (IRS-1) and IRS-2; induced the association of these substrates with phosphatidylinositol 3-kinase and Grb2; and activated Akt kinase and p42/p44 mitogen-activated protein kinases. ATA and EB competed for IGF-I binding to the IGF-IR. ATA was found to be selective for the IGF-IR, whereas EB also activated the insulin receptor. Upon fractionation of commercial ATA by size exclusion chromatography, we found that fractions that enhanced the intensity of tyrosyl-phosphorylated IRS-1/IRS-2 also increased the survival of MCF-7 cells in the presence of cycloheximide, whereas fractions devoid of IRS phosphorylation activity had no survival ability. Taken together, these results suggest that the survival/proliferation-promoting effects of ATA and EB in MCF-7 cells are transduced via the IGF-IR signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11416032     DOI: 10.1210/endo.142.7.8265

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Design of serum-free medium for suspension culture of CHO cells on the basis of general commercial media.

Authors:  Hideo Miki; Mutsumi Takagi
Journal:  Cytotechnology       Date:  2014-08-23       Impact factor: 2.058

2.  Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors.

Authors:  Chad Myskiw; Yvon Deschambault; Kristel Jefferies; Runtao He; Jingxin Cao
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

3.  Zinc supplementation increases protein titer of recombinant CHO cells.

Authors:  Berta Capella Roca; Antonio Alarcón Miguez; Joanne Keenan; Srinivas Suda; Niall Barron; Donal O'Gorman; Padraig Doolan; Martin Clynes
Journal:  Cytotechnology       Date:  2019-08-08       Impact factor: 2.058

4.  Salutary effect of aurintricarboxylic acid on endotoxin- and sepsis-induced changes in muscle protein synthesis and inflammation.

Authors:  Lacee J Laufenberg; Abid A Kazi; Charles H Lang
Journal:  Shock       Date:  2014-05       Impact factor: 3.454

5.  Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases.

Authors:  Anwar M Hashem; Anathea S Flaman; Aaron Farnsworth; Earl G Brown; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

6.  Aurintricarboxylic acid inhibits complement activation, membrane attack complex, and choroidal neovascularization in a model of macular degeneration.

Authors:  Erion Lipo; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-29       Impact factor: 4.799

7.  Aurintricarboxylic acid increases yield of HSV-1 vectors.

Authors:  Peter Pechan; Jeffery Ardinger; Jyothi Ketavarapu; Hillard Rubin; Samuel C Wadsworth; Abraham Scaria
Journal:  Mol Ther Methods Clin Dev       Date:  2014-02-19       Impact factor: 6.698

Review 8.  The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures.

Authors:  Erik De Clercq
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

9.  Gene expression-based screening for inhibitors of PDGFR signaling.

Authors:  Alena A Antipova; Brent R Stockwell; Todd R Golub
Journal:  Genome Biol       Date:  2008-03-01       Impact factor: 13.583

10.  Aurintricarboxylic acid inhibits influenza virus neuraminidase.

Authors:  Hui-Chen Hung; Ching-Ping Tseng; Jinn-Moon Yang; Yi-Wei Ju; Sung-Nain Tseng; Yen-Fu Chen; Yu-Sheng Chao; Hsing-Pang Hsieh; Shin-Ru Shih; John T-A Hsu
Journal:  Antiviral Res       Date:  2008-11-17       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.